Source: Quorum Architects
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • InterCure Ltd. (INCR.U) partners with with international cannabis brand Cookies
  • InterCure will partner with Cookies to open retail locations in Austria and the U.K. in early 2022
  • InterCure will leverage its licensed international supply chain to serve the growing communities of medical cannabis patients in Europe
  • InterCure is a growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer
  • InterCure Ltd. (INCR.U) is trading at C$7.42 at 9:25 am EST

To facilitate its expansion into Europe, InterCure (INCR.U) has announced a partnership with iconic cannabis brand Cookies.

The parties entered into a multi-year agreement under which InterCure expects to establish Cookies stores and medical cannabis pharmacies in Austria and the United Kingdom in early 2022, subject to local regulations.

“As we focus on new territories, it’s vital our customers continue to count on the quality Cookies is known for, which is a value we share with our partners at InterCure,” said Parker Berling, President of Cookies.

“We look forward to reaching audiences in Austria and the United Kingdom and establishing Cookies as a mainstay in each community,” added Berling.

InterCure, a Cookies’ international partner, is already cultivating, manufacturing and distributing Cookies’ GMP standard, branded products through its Cookies’ national medical cannabis pharmacy chain in Israel.

InterCure will leverage its licensed international supply chain to serve the growing communities of medical cannabis patients in Europe.

“Cookies is already one of the most internationally recognized cannabis brands,” said InterCure’s Chief Executive Officer, Alexander Rabinovitch.

InterCure is a growing cannabis company outside of North America. Canndoc, a wholly-owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

InterCure Ltd. (INCR.U) is trading at C$7.42 at 9:25 am EST.

More From The Market Herald

" BioHarvest (CSE:BHSC) predicts 2022 revenue to grow up to 3.5 times

BioHarvest Sciences Inc. (BHSC) expects strong revenue growth to continue in 2022 due to a successful over-delivery of projected revenue targets from last year.

" Icanic Brands (CSE:ICAN) agrees to acquire cannabis extraction company

Icanic Brands Company (ICAN) has signed a definitive agreement to acquire 100 per cent of LEEF Holdings Inc.
Tilray - Denise Faltischek, Head of International and Chief Strategy Officer.

" Tilray (TSX:TLRY) expands Australian medical cannabis offering

Tilray (TLRY) has expanded its medical cannabis product suite in Australia.

" Craftport Cannabis (CSE:CFT) announces $3M private placement

Craftport Cannabis (CFT) has announced a non-brokered private placement for gross proceeds of $3 million.